tiprankstipranks
Pro Medicus Limited (PMCUF)
OTHER OTC:PMCUF
US Market
PMCUF
Pro Medicus Limited
RESEARCH TOOLSreports

Pro Medicus Limited (PMCUF) Stock Forecast & Price Target

38 Followers
See the Price Targets and Ratings of:

PMCUF Analyst Ratings

Strong Buy
10Ratings
Strong Buy
9 Buy
1 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Pro
Medicus Limited
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PMCUF Stock 12 Month Forecast

Average Price Target

$140.09
▲(35.96% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Pro Medicus Limited in the last 3 months. The average price target is $140.09 with a high forecast of $175.60 and a low forecast of $103.95. The average price target represents a 35.96% change from the last price of $103.04.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"85":"$85","202":"$202","114.25":"$114.3","143.5":"$143.5","172.75":"$172.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":175.600075,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$175.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":140.089439425,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$140.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103.94807705,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$103.95</span>\n  </div></div>","useHTML":true}}],"tickPositions":[85,114.25,143.5,172.75,202],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.03,104.92000576923077,110.81001153846154,116.7000173076923,122.59002307692307,128.48002884615386,134.3700346153846,140.2600403846154,146.15004615384615,152.04005192307693,157.93005769230768,163.82006346153847,169.71006923076925,{"y":175.600075,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.03,102.18841841730769,105.34683683461539,108.50525525192307,111.66367366923077,114.82209208653846,117.98051050384615,121.13892892115385,124.29734733846153,127.45576575576922,130.61418417307692,133.77260259038462,136.9310210076923,{"y":140.089439425,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.03,99.40831361923077,99.78662723846153,100.1649408576923,100.54325447692308,100.92156809615385,101.29988171538461,101.67819533461538,102.05650895384615,102.43482257307691,102.8131361923077,103.19144981153846,103.56976343076923,{"y":103.94807705,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":146.582,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180.815,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":185.288,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.601,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":196.386,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":200.981,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.417,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.492,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.192,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.032,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.758,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.03,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$175.60Average Price Target$140.09Lowest Price Target$103.95
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on PMCUF
Jennifer Xu
Jefferies
Jefferies
$105.36
Buy
2.25%
Upside
Reiterated
05/25/26
Pro Medicus Limited (PMCUF) Gets a Buy from Jefferies
J.P. Morgan Analyst forecast on PMCUF
Chris Cooper
J.P. Morgan
J.P. Morgan
$149.01
Buy
44.61%
Upside
Reiterated
05/18/26
Pro Medicus Limited (PMCUF) Receives a Buy from J.P. Morgan
RBC Capital Analyst forecast on PMCUF
Jackson Lee
RBC Capital
Not Ranked
RBC Capital
$136.18→$139.76
Hold
35.64%
Upside
Reiterated
05/18/26
Analysts Conflicted on These Healthcare Names: Design Therapeutics (NASDAQ: DSGN), Pro Medicus Limited (Other OTC: PMCUF) and Boston Scientific (NYSE: BSX)
Ord Minnett Analyst forecast on PMCUF
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
$157.68→$150.51
Buy
46.07%
Upside
Reiterated
05/14/26
Ord Minnett Sticks to Their Buy Rating for Pro Medicus Limited (PMCUF)
Canaccord Genuity Analyst forecast on PMCUF
Madeleine Williams
Canaccord Genuity
Canaccord Genuity
$129.6→$120.86
Buy
17.29%
Upside
Reiterated
05/12/26
Canaccord Genuity Sticks to Its Buy Rating for Pro Medicus Limited (PMCUF)
Morgan Stanley Analyst forecast on PMCUF
Chris Boulus
Morgan Stanley
Morgan Stanley
$143.35
Buy
39.12%
Upside
Reiterated
04/30/26
Morgan Stanley Sticks to Their Buy Rating for Pro Medicus Limited (PMCUF)
Morgans Analyst forecast on PMCUF
Iain Wilkie
Morgans
Morgans
$207.85→$150.51
Buy
46.07%
Upside
Reiterated
04/19/26
Analysts Are Bullish on These Healthcare Stocks: Somnomed Limited (SOMNF), Pro Medicus Limited (PMCUF)
Bell Potter Analyst forecast on PMCUF
John Hester
Bell Potter
Bell Potter
$172.02→$161.98
Buy
57.20%
Upside
Reiterated
04/14/26
Analysts Are Bullish on These Healthcare Stocks: Pro Medicus Limited (PMCUF), Telix Pharmaceuticals (TLPPF)
Citi Analyst forecast on PMCUF
Laura Sutcliffe
Citi
Citi
$215.02→$175.6
Buy
70.42%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Pro Medicus Limited (Other OTC: PMCUF) and Amgen (NASDAQ: AMGN)
MA Financial Group Analyst forecast on PMCUF
Sarah Mann
MA Financial Group
MA Financial Group
$101.09→$103.95
Buy
0.88%
Upside
Upgraded
03/24/26
Pro Medicus Limited (PMCUF) was upgraded to a Buy Rating at MA Financial Group
Macquarie Analyst forecast on PMCUF
Unknown Analyst
Macquarie
Not Ranked
Macquarie
$208.78→$174.88
Buy
69.72%
Upside
Reiterated
02/13/26
Macquarie Reaffirms Their Buy Rating on Pro Medicus Limited (PMCUF)
Goldman Sachs Analyst forecast on PMCUF
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$244.41→$193.52
Buy
87.81%
Upside
Reiterated
02/05/26
Goldman Sachs Reaffirms Their Buy Rating on Pro Medicus Limited (PMCUF)
UBS Analyst forecast on PMCUF
David Low
UBS
UBS
$215.02
Hold
108.68%
Upside
Reiterated
08/14/25
J.P. Morgan Remains a Hold on Pro Medicus Limited (PMCUF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on PMCUF
Jennifer Xu
Jefferies
Jefferies
$105.36
Buy
2.25%
Upside
Reiterated
05/25/26
Pro Medicus Limited (PMCUF) Gets a Buy from Jefferies
J.P. Morgan Analyst forecast on PMCUF
Chris Cooper
J.P. Morgan
J.P. Morgan
$149.01
Buy
44.61%
Upside
Reiterated
05/18/26
Pro Medicus Limited (PMCUF) Receives a Buy from J.P. Morgan
RBC Capital Analyst forecast on PMCUF
Jackson Lee
RBC Capital
Not Ranked
RBC Capital
$136.18→$139.76
Hold
35.64%
Upside
Reiterated
05/18/26
Analysts Conflicted on These Healthcare Names: Design Therapeutics (NASDAQ: DSGN), Pro Medicus Limited (Other OTC: PMCUF) and Boston Scientific (NYSE: BSX)
Ord Minnett Analyst forecast on PMCUF
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
$157.68→$150.51
Buy
46.07%
Upside
Reiterated
05/14/26
Ord Minnett Sticks to Their Buy Rating for Pro Medicus Limited (PMCUF)
Canaccord Genuity Analyst forecast on PMCUF
Madeleine Williams
Canaccord Genuity
Canaccord Genuity
$129.6→$120.86
Buy
17.29%
Upside
Reiterated
05/12/26
Canaccord Genuity Sticks to Its Buy Rating for Pro Medicus Limited (PMCUF)
Morgan Stanley Analyst forecast on PMCUF
Chris Boulus
Morgan Stanley
Morgan Stanley
$143.35
Buy
39.12%
Upside
Reiterated
04/30/26
Morgan Stanley Sticks to Their Buy Rating for Pro Medicus Limited (PMCUF)
Morgans Analyst forecast on PMCUF
Iain Wilkie
Morgans
Morgans
$207.85→$150.51
Buy
46.07%
Upside
Reiterated
04/19/26
Analysts Are Bullish on These Healthcare Stocks: Somnomed Limited (SOMNF), Pro Medicus Limited (PMCUF)
Bell Potter Analyst forecast on PMCUF
John Hester
Bell Potter
Bell Potter
$172.02→$161.98
Buy
57.20%
Upside
Reiterated
04/14/26
Analysts Are Bullish on These Healthcare Stocks: Pro Medicus Limited (PMCUF), Telix Pharmaceuticals (TLPPF)
Citi Analyst forecast on PMCUF
Laura Sutcliffe
Citi
Citi
$215.02→$175.6
Buy
70.42%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Pro Medicus Limited (Other OTC: PMCUF) and Amgen (NASDAQ: AMGN)
MA Financial Group Analyst forecast on PMCUF
Sarah Mann
MA Financial Group
MA Financial Group
$101.09→$103.95
Buy
0.88%
Upside
Upgraded
03/24/26
Pro Medicus Limited (PMCUF) was upgraded to a Buy Rating at MA Financial Group
Macquarie Analyst forecast on PMCUF
Unknown Analyst
Macquarie
Not Ranked
Macquarie
$208.78→$174.88
Buy
69.72%
Upside
Reiterated
02/13/26
Macquarie Reaffirms Their Buy Rating on Pro Medicus Limited (PMCUF)
Goldman Sachs Analyst forecast on PMCUF
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$244.41→$193.52
Buy
87.81%
Upside
Reiterated
02/05/26
Goldman Sachs Reaffirms Their Buy Rating on Pro Medicus Limited (PMCUF)
UBS Analyst forecast on PMCUF
David Low
UBS
UBS
$215.02
Hold
108.68%
Upside
Reiterated
08/14/25
J.P. Morgan Remains a Hold on Pro Medicus Limited (PMCUF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pro Medicus Limited

3 Months
Chris CooperJ.P. Morgan
Success Rate
9/11 ratings generated profit
82%
Average Return
+11.98%
Copying Chris Cooper's trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +11.98% per trade.
1 Year
Chris CooperJ.P. Morgan
Success Rate
10/11 ratings generated profit
91%
Average Return
+62.92%
Copying Chris Cooper's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +62.92% per trade.
2 Years
Chris CooperJ.P. Morgan
Success Rate
10/11 ratings generated profit
91%
Average Return
+143.45%
Copying Chris Cooper's trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +143.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PMCUF Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
7
13
11
11
5
Buy
2
1
2
4
5
Hold
1
3
3
4
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
17
16
19
13
In the current month, PMCUF has received 10 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. PMCUF average Analyst price target in the past 3 months is 140.09.
Each month's total comprises the sum of three months' worth of ratings.

PMCUF Financial Forecast

PMCUF Earnings Forecast

Next quarter’s earnings estimate for PMCUF is $0.67 with a range of $0.50 to $1.31. The previous quarter’s EPS was $1.17. PMCUF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PMCUF has Performed in-line its overall industry.
Next quarter’s earnings estimate for PMCUF is $0.67 with a range of $0.50 to $1.31. The previous quarter’s EPS was $1.17. PMCUF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PMCUF has Performed in-line its overall industry.

PMCUF Sales Forecast

Next quarter’s sales forecast for PMCUF is $95.74M with a range of $91.66M to $97.96M. The previous quarter’s sales results were $89.35M. PMCUF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PMCUF has Performed in-line its overall industry.
Next quarter’s sales forecast for PMCUF is $95.74M with a range of $91.66M to $97.96M. The previous quarter’s sales results were $89.35M. PMCUF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PMCUF has Performed in-line its overall industry.

PMCUF Stock Forecast FAQ

What is PMCUF’s average 12-month price target, according to analysts?
Based on analyst ratings, Pro Medicus Limited’s 12-month average price target is 140.09.
    What is PMCUF’s upside potential, based on the analysts’ average price target?
    Pro Medicus Limited has 35.96% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PMCUF a Buy, Sell or Hold?
          Pro Medicus Limited has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Pro Medicus Limited’s price target?
            The average price target for Pro Medicus Limited is 140.09. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $175.60 ,the lowest forecast is $103.95. The average price target represents 35.96% Increase from the current price of $103.04.
              What do analysts say about Pro Medicus Limited?
              Pro Medicus Limited’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of PMCUF?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.